Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

JNJ-78901563

Generic Name: JNJ-78901563

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Phase 3

Completed

Posted: 2023/11/18

Sponsor:Janssen Research & D...

ID:NCT06134804

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Phase 3

Active, not recruiting

Posted: 2021/05/24

Sponsor:Janssen Research & D...

ID:NCT04899336

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Sanofi and J&J Join Forces in $175M Deal to Combat E. coli Sepsis with Novel Vaccine

3 months ago

Sanofi has invested $175 million upfront to partner with Johnson & Johnson's Janssen unit on ExPEC9V, a phase 3 vaccine targeting extraintestinal pathogenic E. coli infections.

Sanofi and J&J Halt Phase 3 Trial of E. coli Vaccine Due to Insufficient Efficacy

3 months ago

The E.mbrace phase 3 trial evaluating Sanofi and Johnson & Johnson's vaccine candidate against invasive E. coli disease has been discontinued following an independent interim analysis showing insufficient efficacy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy